Neurocrine Biosciences
NBIX
#1374
Rank
HK$120.49 B
Marketcap
HK$1,190
Share price
-3.01%
Change (1 day)
10.74%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

P/S ratio for Neurocrine Biosciences (NBIX)

P/S ratio as of November 2026 (TTM): 4.19

According to Neurocrine Biosciences 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.20. At the end of 2026 the company had a P/S ratio of 3.93.

P/S ratio history for Neurocrine Biosciences from 2001 to 2026

PS ratio at the end of each year

Year P/S ratio Change
20263.93-19.77%
20254.90-18.24%
20245.99-12.62%
20236.86-11.06%
20227.718.2%
20217.13-16.75%
20208.56-31.97%
201912.6-12.4%
201814.4-66.18%
201742.5-81.05%
2016224-9.2%
2015247
2014N/A-100%
20132162204.11%
20129.3554.16%
20116.07-51.52%
201012.5-69.11%
200940.530.41%
200831.1-78.11%
20071421310.15%
200610.1-46.46%
200518.8-11.08%
200421.152.7%
200313.8-82.15%
200277.6105.49%
200137.8

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Pfizer
PFE
2.47-41.03%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
7.74 84.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
13.9 232.55%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
13.2 214.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
10.4 148.39%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
1.51-64.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
0.6315-84.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
15.1 259.02%๐Ÿ‡ฌ๐Ÿ‡ง UK